Brought to you by 
Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal
18 Oct 2021
Executive Summary
Celgene Corp. licensed exclusive rights to BeiGene (Beijing) Co. Ltd.’s PD-1 inhibitor BGBA317 as part of a deal that also sees BeiGene acquiring Celgene’s Chinese commercial operations and rights in China to key Celgene therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice